Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 183.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,875 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Kymera Therapeutics makes up about 1.0% of Nan Fung Group Holdings Ltd’s portfolio, making the stock its 25th biggest position. Nan Fung Group Holdings Ltd’s holdings in Kymera Therapeutics were worth $1,242,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the company. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Kymera Therapeutics during the 4th quarter worth approximately $251,000. First Trust Advisors LP increased its stake in shares of Kymera Therapeutics by 43.2% in the 4th quarter. First Trust Advisors LP now owns 176,220 shares of the company’s stock valued at $7,089,000 after purchasing an additional 53,175 shares in the last quarter. PEAK6 LLC acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $302,000. Affinity Asset Advisors LLC purchased a new position in Kymera Therapeutics during the fourth quarter valued at $1,609,000. Finally, Summit Investment Advisors Inc. lifted its stake in Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after buying an additional 406 shares in the last quarter.

Insiders Place Their Bets

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. The trade was a 3.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the transaction, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,659 shares of company stock valued at $324,567. 15.82% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on KYMR shares. HC Wainwright lifted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens reissued an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Citigroup initiated coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $25.97 on Friday. The stock has a market cap of $1.69 billion, a P/E ratio of -11.10 and a beta of 2.22. Kymera Therapeutics, Inc. has a 1 year low of $19.45 and a 1 year high of $53.27. The stock has a 50-day simple moving average of $30.47 and a 200-day simple moving average of $39.04.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.